Eprenetapopt
Small moleculeexperimental
Clinical trial activity
13 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
11
Phase 3
1
Phase 4
0
Earliest trial started May 1, 2009 (NCT00900614)
Timeline
Indications
Studied for
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Transitional Cell · Phase 1/Phase 2
- Esophageal Neoplasms · Phase 1/Phase 2
- GATA2 Deficiency · Phase 2
- Hematologic Neoplasms · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1/Phase 2
- Leukemia, Myeloid, Acute · Phase 1/Phase 2
- Leukemia, Myelomonocytic, Chronic · Phase 1/Phase 2
- Lymphoma, Mantle-Cell · Phase 2
- Lymphoma, Non-Hodgkin · Phase 1/Phase 2
- Melanoma · Phase 1/Phase 2
- Myelodysplastic Syndromes · Phase 3
- Myeloproliferative Disorders · Phase 1/Phase 2
- Neoplasms · Phase 1/Phase 2
- Ovarian Neoplasms · Phase 2
- Prostatic Neoplasms · Phase 1
- Stomach Neoplasms · Phase 1/Phase 2
- Urinary Bladder Neoplasms · Phase 1/Phase 2
Mechanism of action
- Cellular tumor antigen p53STABILISER
Cellular tumor antigen p53 stabiliser
Mechanism not fully elucidated. In addition to activation of p53, ARP-246 also produces sustained oxidative stress; remaining mutant p53-containing cells may be more susceptible to OS.
- Cellular tumor antigen p53Supplementation
TP53 supplementation
Chemistry & pharmacology
Loading structure…
SMILES
COCC1(CO)C(=O)C2CCN1CC2- Mol. weight
- 199.25 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL3186011 ↗
Also known as
- 2-hydroxymethyl-2-methoxymethylazabicyclo(2.2.2)octan-3-one
- apr-246
- apr-246
- apr-246
- apr-246
- prima-1(met)
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04990778 | Phase 2 | Nov 30, 2021 | University of Texas at Houston |
| NCT04419389 | Phase 1/Phase 2 (Phase 2) | Sep 30, 2020 | Aprea Therapeutics AB, Theradex |
| NCT04383938 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2020 | Aprea Therapeutics AB, Theradex |
| NCT04214860 | Phase 1 | Dec 13, 2019 | Aprea Therapeutics AB |
| NCT03931291 | Phase 2 | May 30, 2019 | Aprea Therapeutics AB, University of South Florida |
| NCT03745716 | Phase 3 | Jan 11, 2019 | Aprea Therapeutics AB, University of South Florida |
| NCT03588078 | Phase 1/Phase 2 (Phase 2) | Sep 15, 2018 | Aprea Therapeutics AB, Groupe Francophone des Myelodysplasies, service Hématologie Séniors Hôpital Saint Louis |
| NCT03391050 | Phase 1/Phase 2 (Phase 2) | Jan 18, 2018 | Aprea Therapeutics AB, Free University of Brussels |
| NCT03268382 | Phase 2 | Jul 31, 2017 | Aprea Therapeutics AB, University of Edinburgh |
| NCT03072043 | Phase 1/Phase 2 (Phase 2) | May 5, 2017 | University of South Florida |
| NCT02999893 | Phase 1/Phase 2 (Phase 2) | Apr 11, 2017 | Peter MacCallum Cancer Centre |
| NCT02098343 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2014 | Aprea Therapeutics AB, University of Liverpool |
| NCT00900614 | Phase 1 | May 1, 2009 | Aprea Therapeutics AB, Karolinska Institute |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aprea Therapeutics AB | For profit | 10 | 9 | 3 | 2009 |
| University of South Florida | Academic/Hospital | 3 | 1 | 2 | 2017 |
| Theradex | For profit | 2 | 0 | 1 | 2020 |
| Free University of Brussels | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Groupe Francophone des Myelodysplasies | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Karolinska Institute | Academic/Hospital | 1 | 0 | 1 | 2009 |
| Peter MacCallum Cancer Centre | Academic/Hospital | 1 | 1 | 1 | 2017 |
| service Hématologie Séniors Hôpital Saint Louis | Academic/Hospital | 1 | 0 | 1 | 2018 |
| University of Edinburgh | Academic/Hospital | 1 | 0 | 1 | 2017 |
| University of Liverpool | Academic/Hospital | 1 | 0 | 1 | 2014 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2021 |
11 organizations
Page 1 / 1